Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Fu Y, Liu S, Zeng S, Shen H. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 38(1), 396 (2019).
  MedlineGoogle Scholar
• 2. Yau T, Park JW, Finn RS et al. LBA38_PR CheckMate 459: a randomized, multi-center Phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann. Oncol. 30(Suppl. 5), V874–V875 (2019).
  Google Scholar
• 3. Finn RS, Ryoo BY, Merle P et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, Phase III trial. J. Clin. Oncol. 38(3), 193–202 (2019).
  MedlineGoogle Scholar
• 4. Finn RS, Qin S, Ikeda M et al. Atezolizumab plusbevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382(20), 1894–1905 (2020). •• Demonstrates clinically meaningful improvement with atezolizumab plus bevacizumab over sorafenib for overall survival and progression-free survival for patients with unresectable hepatocellular carcinoma.
  Medline CASGoogle Scholar
• 5. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378–390 (2008).
  Medline CASGoogle Scholar
• 6. Kudo M, Finn RS, Qin S et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trial. Lancet 391(10126), 1163–1173 (2018).
  Medline CASGoogle Scholar
• 7. Bruix J, Qin S, Merle P et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet 389(10064), 56–66 (2017).
  Medline CASGoogle Scholar
• 8. Abou-Alfa GK, Meyer T, Cheng A-L et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 379(1), 54–63 (2018). • Pivotal Phase III trial that resulted in the approval of cabozantinib for treatment of patients with previously treated advanced hepatocellular carcinoma.
  Medline CASGoogle Scholar
• 9. Zhu AX, Kang YK, Yen CJ et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet Oncol. 20(2), 282–296 (2019).
  Medline CASGoogle Scholar
• 10. McDermott DF, Huseni MA, Atkins MB et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24(6), 749–757 (2018).
  Medline CASGoogle Scholar
• 11. Motzer RJ, Penkov K, Haanen J et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380(12), 1103–1115 (2019).
  Medline CASGoogle Scholar
• 12. Nadal RM, Mortazavi A, Stein M et al. Results of Phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies. J. Clin. Oncol. 36(Suppl. 6), 515–515 (2018).
  MedlineGoogle Scholar
• 13. Rini BI, Plimack ER, Stus V et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380(12), 1116–1127 (2019).
  Medline CASGoogle Scholar
• 14. Yakes FM, Chen J, Tan J et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Ther. 10(12), 2298–2308 (2011). • Provides preclinical findings supporting the promise of cabozantinib to inhibit tumor angiogenesis, tumor growth and metastasis.
  Medline CASGoogle Scholar
• 15. Apolo AB, Parnes HL, Francis DC et al. A Phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC). J. Clin. Oncol. 34(Suppl. 15), 4534–4534 (2016).
  Google Scholar
• 16. Apolo AB, Tomita Y, Lee M-J et al. Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma. J. Clin. Oncol. 32(Suppl. 15), 4501–4501 (2014).
  Google Scholar
• 17. Yau T, Zagonel V, Santoro A et al. Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. J. Clin. Oncol. 38(Suppl. 4), Abstract 478 (2020).
  Google Scholar
• 18. Agarwal N, Vaishampayan U, Green M et al. Phase 1b study (COSMIC-021) of cabozantinib in combination with atezolizumab: Results of the dose escalation stage. Ann. Oncol. 29(Suppl. 8), Abstract 872P (2018). •• The preliminary analysis of this study established the recommended dose of the combination cabozantinib and atezolizumab and reported encouraging activity in patients with renal cell carcinoma.
  Google Scholar
• 19. Pal SK, Vaishampayan UN, Castellano DE et al. Phase Ib (COSMIC-021) trial of cabozantinib (C) in urothelial carcinoma (UC) or C in combination with atezolizumab (A) in patients (pts) with UC, castrate resistant prostate cancer (CRPC) or renal cell carcinoma (RCC). J. Clin. Oncol. 37(Suppl. 7), TPS683 (2019).
  Google Scholar
• 20. El-Khoueiry AB, Sangro B, Yau T et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, Phase 1/2 dose escalation and expansion trial. Lancet 389(10088), 2492–2502 (2017).
  Medline CASGoogle Scholar
• 21. Zhu AX, Finn RS, Edeline J et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label Phase II trial. Lancet Oncol. 19(7), 940–952 (2018).
  MedlineGoogle Scholar
• 22. Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528), 563–567 (2014).
  Medline CASGoogle Scholar
• 23. McDermott DF, Sosman JA, Sznol M et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a Phase Ia study. J. Clin. Oncol. 34(8), 833–842 (2016).
  Medline CASGoogle Scholar
• 24. Rini BI, Powles T, Atkins MB et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, Phase III, randomised controlled trial. Lancet 393(10189), 2404–2415 (2019).
  MedlineGoogle Scholar
• 25. Lee M, Ryoo B-Y, Hsu C-H et al. Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC). Ann. Oncol. 30(Suppl. 5), Abstract LBA39 (2019).
  Google Scholar
• 26. Bergerot P, Lamb P, Wang E, Pal SK. Cabozantinib in combination with immunotherapy for advanced renal cell carcinoma and urothelial carcinoma: rationale and clinical evidence. Mol. Cancer Ther. 18(12), 2185–2193 (2019). •• Review of the combination of cabozantinib with immunotherapy, including discussion of the unique immunomodulatory profile of cabozantinib as well as the preclinical and clinical studies supporting these combinations.
  Medline CASGoogle Scholar
• 27. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature 541(7637), 321–330 (2017).
  Medline CASGoogle Scholar
• 28. Terme M, Colussi O, Marcheteau E, Tanchot C, Tartour E, Taieb J. Modulation of immunity by antiangiogenic molecules in cancer. Clin. Dev. Immunol. 2012, 492920 (2012).
  MedlineGoogle Scholar
• 29. Wallin JJ, Bendell JC, Funke R et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat. Commun. 7, 12624 (2016).
  Medline CASGoogle Scholar
• 30. Ott PA, Hodi FS, Buchbinder EI. Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data. Front. Oncol. 5, 202 (2015).
  MedlineGoogle Scholar
• 31. Voron T, Marcheteau E, Pernot S et al. Control of the immune response by pro-angiogenic factors. Front. Oncol. 4, 70 (2014).
  MedlineGoogle Scholar
• 32. Akalu YT, Rothlin CV, Ghosh S. TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. Immunol. Rev. 276(1), 165–177 (2017).
  Medline CASGoogle Scholar
• 33. Kwilas AR, Ardiani A, Donahue RN, Aftab DT, Hodge JW. Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J. Transl. Med. 12, 294 (2014).
  MedlineGoogle Scholar
• 34. Balan M, Mier Y, Teran E, Waaga-Gasser AM et al. Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. J. Biol. Chem. 290(13), 8110–8120 (2015).
  Medline CASGoogle Scholar
• 35. Glodde N, Bald T, Van Den Boorn-Konijnenberg D et al. Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy. Immunity 47(4), 789–802.e789 (2017).
  Medline CASGoogle Scholar
• 36. Hübel J, Hieronymus T. HGF/Met-signaling contributes to immune regulation by modulating tolerogenic and motogenic properties of dendritic cells. Biomedicines 3(1), 138–148 (2015).
  Medline CASGoogle Scholar
• 37. Aguilera TA, Rafat M, Castellini L et al. Reprogramming the immunological microenvironment through radiation and targeting Axl. Nat. Commun. 7, 13898 (2016).
  Medline CASGoogle Scholar
• 38. Guo Z, Li Y, Zhang D, Ma J. Axl inhibition induces the antitumor immune response, which can be further potentiated by PD-1 blockade in the mouse cancer models. Oncotarget 8(52), 89761–89774 (2017).
  MedlineGoogle Scholar
• 39. Paolino M, Penninger JM. The role of TAM family receptors in immune cell function: implications for cancer therapy. Cancers (Basel) 8(10), 97 (2016).
  MedlineGoogle Scholar
• 40. Graham DK, Deryckere D, Davies KD, Earp HS. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat. Rev. Cancer 14(12), 769–785 (2014).
  Medline CASGoogle Scholar
• 41. Lu X, Horner JW, Paul E et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 543(7647), 728–732 (2017). • Provides preclinical findings in a murine model of castration-resistant prostate cancer supporting the combination of cabozantinib and immune checkpoint blockade.
  Medline CASGoogle Scholar
• 42. Duda DG, Ziehr DR, Guo H et al. Effect of cabozantinib treatment on circulating immune cell populations in patients with metastatic triple-negative breast cancer (TNBC). J. Clin. Oncol. 34(Suppl. 15), 1093–1093 (2016).
  Google Scholar
• 43. Verzoni E, Ferro S, Procopio G et al. Potent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pretreated metastatic renal cell carcinoma (mRCC) patients. Ann. Oncol. 29(Suppl. 8), viii303–viii331 (2018).
  Google Scholar
• 44. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228–247 (2009).
  Medline CASGoogle Scholar
• 45. Hodi FS, Ballinger M, Lyons B et al. Immune-modified Response Evaluation Criteria in Solid Tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy. J. Clin. Oncol. 36(9), 850–858 (2018).
  MedlineGoogle Scholar
• 46. Herdman M, Gudex C, Lloyd A et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual. Life Res. 20(10), 1727–1736 (2011).
  Medline CASGoogle Scholar
• 47. Abou-Alfa GK, Chan SL, Furuse J et al. A randomized, multicenter Phase III study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study. J. Clin. Oncol. 36(Suppl. 15), TPS4144–TPS4144 (2018).
  Google Scholar
• 48. Llovet JM, Kudo M, Cheng A-L et al. Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase III LEAP-002 study. J. Clin. Oncol. 37(Suppl. 15), TPS4152–TPS4152 (2019).
  Google Scholar